Abstract
Endometrial cancer is the most common gynaecological malignancy. Although no specific gene or genes have been linked to the majority of cases of endometrial cancer, several well-characterized oncogenes and tumour-suppressor genes have been implicated in endometrial carcinogenesis. Approximately 80% of endometrial cancer cases are type I tumours, which are usually well differentiated and endometrioid in histology, and are associated with a history of unopposed oestrogen exposure or other hyperoestrogenic risk factors such as obesity. Oestrogen and selective oestrogen-receptor modulators (SERMs) are implicated in endometrial carcinogenesis through regulation of gene transcription. Oestrogen and SERMs exert their carcinogenic roles in the endometrium through their downstream molecular effectors such as PAX2 (paired box gene 2).